Bookmark
Print
Recommend
  • Home
  • About PBS/IC
    • Overview
    • Nomenclature
    • Causes
    • Diagnosis
      • Overview
      • Diagnostic flow
      • NIDDK
      • Differential diagnosis
    • Management
    • Patients
      • Patient quotes
      • Case studies
    • COB Foundation Survey
      • Overview
      • Diagnosis
      • Symptoms
      • Quality of life
      • Economic impact
    • Clinical Phenotyping
      • Background to UPOINT
      • What is UPOINT
      • UPOINT research
    • References
  • Product information
    • Overview
    • Efficacy
      • Study 1
      • Study 2
    • Tolerability
    • Volume
    • Optimum dose of chondroitin sulfate
    • Budget impact
    • Mode of Action
    • Rationale for using chondroitin sulfate for PBS/IC
      • Importance of bladder GAG layer
      • Importance of chondroitin sulfate in bladder wall GAG layer
      • Dr Hurst Presentation video
    • How to administer Uracyst
    • Recommended treatment plan
    • References
  • Resources
  • KOL webcast
  • Prescribing information & adverse incident reporting
  • Request a call back

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Dr Nickel
Interview

Click here
to watch the
interview in full

MOA
Animation

Watch the
mode of action video now

           Email
           updates

Sign up today and receive regular website updates

Where am I: Product information > References

References

  1. Nickel JC et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU International. Epub 3 September 2008.
  2. Nickel JC et al. Chondroitin sulfate is a promising therapy for interstitial cystitis/painful bladder syndrome (IC/PBS). Abstract presented at NAUA October 2009.
  3. Data on file.
  4. Hauser P et al. Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate. J.Urol. 2009; 182: 2477-82.
  5. Personal communication (May 2009) with Dr RE Hurst, co-author of Hauser P et al. Restoring barrier function to acid-damaged bladder by intravesical chondroitin sulfate. J.Urol. 2009; 182: 2477-82.
  6. Hurst RE, Roy J and Parsons C. The role of Glycosaminoglycans in normal bladder physiology and the pathophysiology of interstitial cystitis. Interstitial Cystitis. 1997. Philadelphia. Lippincott-Raven Publishers.
  7. Hurst RE. A deficit of proteoglycans on the bladder uroepithelium in interstitial cystitis. European Urology Supplements. 2 (2003) 10-13.
  8. Rosenberg M, Newman D and Page S. Interstitial cystitis/painful bladder syndrome: Symptom recognition is key to early identification, treatment. Cleveland Clinic Journal of Medicine. 2007; 74 (3): S54-62.
  9. Kelada E and Jones A. Interstitial cystitis. Arch Gynecol Obstet 2007; 275:223-229.
  10. Hurst RE. Structure, function and pathology of proteoglycans and glycosaminoglycans in the urinary tract.  World Journal of Urology 1994; 12: 3-10. 
  11. Hurst RE. & Zebrowski R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. The Journal of Urology. 1994; 152:1641-1644.
  12. Proteoglycans. School of Crystallography, University of London. www.cryst.bbk.ac.uk. Accessed 5th February 2009.
  13. Kyker K, Coffman J, Hurst RE.  Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder. BMC Urology 2005; 5:4.
  14. Cystistat Product Monograph.
  15. Gepan Instill Business Case. 04/2008.

 

Home | About PBS/IC | Product information | Resources | KOL webcast | Prescribing information & adverse incident reporting | Request a call back | Contact us | Privacy | Sitemap | Copyright